For US health-care professionals only. Prescribing Information

A single oral dose as part of an antiemetic regimen

VARUBI® (rolapitant) is administered approximately 1 to 2 hours before chemotherapy1

No dose adjustment of dexamethasone is required with VARUBI, as there are no drug interactions between VARUBI and dexamethasone.1

VARUBI is supplied as a single dose wallet card containing two 90-mg tablets.

  • A single oral dose of VARUBI provides flexibility of administration; it may be given with either oral or intravenous (IV) 5-hydroxytryptamine-3 (serotonin) receptor antagonists (5-HT3 RAs) and dexamethasone1
  • VARUBI can be administered with or without food1
  • Administer VARUBI prior to the initiation of each chemotherapy cycle, but at no less than 2-week intervals1

Combined antiemetic regimen dosing with VARUBI, a 5-HT3 RA, and dexamethasone1

For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy (HEC and MEC)

5-HT3, 5-hydroxytryptamine-3 (serotonin); HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; RA, receptor antagonist.

Drug interactions

  • VARUBI is an inhibitor of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). Increased plasma concentrations of BCRP and P-gp substrates with a narrow therapeutic index may result in potential adverse reactions. Monitor for adverse reactions related to the concomitant drug if use with VARUBI cannot be avoided
  • Avoid use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers (eg, rifampin) as significantly reduced plasma concentrations of VARUBI can decrease the efficacy of VARUBI

See the emetogenic potential of common chemotherapy regimens and agents